Bone Sci.

Bio is at the forefront of soft tissue restoration innovation, driven by its novel self-assembly peptide hydrogel platform technology.

Its mission is clear: to reshape the landscape of the $50 Billion cosmetic medicine market, specifically addressing the substantial gap in medium to large-volume injectable fillers.Through its groundbreaking Matrix-Guided Fat Grafting (MGFG) approach, the company is pioneering minimally invasive, long-lasting, and natural-looking fat grafting, redefining possibilities from facial and body contouring to breast reconstruction.

Following the successful completion of a comprehensive preclinical program, encompassing small and large animal models, Bone Sci Bio plans for a first clinical study in 2024.